Skip to main content

Table 1 Demographic and clinical characteristics of the patients in the cohort and stratified by the occurrence of specific opportunistic illnesses

From: Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil

  Tuberculosis Esophageal candidiasis Cerebral toxoplasmosis PCP All patientsa  
  N = 177 N = 100 N = 70 N = 55 N = 2835 p-value
Incidence rateb (CI 95 %) 15.3 (13.2, 17.7) 8.6 (7.1, 10.5) 6.0 (4.8, 7.6) 4.8 (367, 6.2) <0.001
Age, median (IQR) 35.4 (28.4,41.5) 38.6 (32.6,45) 33.8 (28.1,40.9) 39.1 (29.6,45.1) 35.6 (28.7,42.7) 0.02
 18–29 years (%) 50 (28.2) 15 (15) 21 (30) 13 (23.6) 750 (26.5) 0.05
 30–39 years (%) 67 (37.9) 36 (36) 27 (38.6) 13 (23.6) 1035 (36.5)  
 40–49 years (%) 46 (26) 34 (34) 16 (22.9) 19 (34.5) 731 (25.8)  
 50+ years (%) 14 (7.9) 15 (15) 6 (8.6) 10 (18.2) 319 (11.3)  
Gender-risk       0.21
 Women 57 (32.2) 41 (41) 27 (38.6) 11 (20) 930 (32.8)  
 Heterossexual men 59 (33.3) 27 (27) 23 (32.9) 22 (40) 833 (29.4)  
 MSM 61 (34.5) 32 (32) 20 (28.6) 22 (40) 1072 (37.8)  
Race/ethnicity       0.12
 White (%) 73 (41.2) 40 (40) 29 (41.4) 32 (58.2) 1415 (49.9)  
 Non-white (%) 104 (58.8) 60 (60) 41 (58.6) 23 (41.8) 1420 (50.1)  
Educational level       0.03
 0–8 years (%) 117 (66.1) 66 (66) 48 (68.6) 25 (45.5) 1399 (49.3)  
 9+ years (%) 60 (33.9) 34 (34) 22 (31.4) 30 (54.5) 1436 (50.7)  
Nadir CD4 T-cell count (cells/mm3)      
Median (IQR) 107 (48,218) 74.5 (21,188.2) 63.5 (20,159.5) 55 (12,146) 196 (71,311.5) 0.002
 <50 (%) 45 (25.4) 39 (39) 33 (47.1) 25 (45.5) 549 (19.4) 0.03
 50–199 (%) 82 (46.3) 39 (39) 27 (38.6) 22 (40) 898 (31.7)  
 200–349 (%) 40 (22.6) 17 (17) 8 (11.4) 5 (9.1) 847 (29.9)  
 350+ (%) 10 (5.6) 5 (5) 2 (2.9) 3 (5.5) 541 (19.1)  
Opportunistic illness at enrolmment 44 (24.9) 43 (43) 35 (50) 21 (38.2) 211 (7.4) <0.001
cART use during follow-up (%) 30 (16.9) 10 (10) 12 (17.1) 8 (14.5) 1878 (66.2) 0.43
Time of cART use in yearsc, median (IQR) 1.1 (0.6,2.7) 0.8 (0.4,1.3) 0.6 (0.1,1.6) 1.7 (1.1,2.1) 2.2 (0.9,4.1) 0.32
  1. cART combination antiretroviral therapy, PCP Pneumocystis jiroveci pneumonia, HR, hazard ratio, CI confidence interval, MSM men who have sex with men
  2. aIncludes the entire study population
  3. bPer 1000 person-years
  4. cFor those who used cART before end of follow-up